Compare Crispr Therapeutics AG (CRSP) vs Ecolab Inc. (ECL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Ecolab Inc. — how do they compare? Crispr Therapeutics AG trades at $50.76 (market cap $4.97B), while Ecolab Inc. trades at $269.19 (market cap $75.92B). The key difference: Ecolab Inc. is far larger — about 15.3× Crispr Therapeutics AG's market cap, and Ecolab Inc. pays a 1.08% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | ECL | |
|---|---|---|
Market Cap | $4.97B | $75.92B |
Sector | Health | Consumer Cyclical |
52-Week High | $76.78 | $308.35 |
52-Week Low | $44.34 | $245.73 |
Enterprise Value | $3.32B | $84.66B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
ECL trades at $271.85, down 0.9% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $327.43, implying significant upside. Recent financials show revenue growth to $16.08B in 2025 and a net income margin of 12.8%, though earnings have been mixed with a Q2 2026 estimate of $2.08 pending. The company's acquisition of CoolIT for $4.75B strengthens its AI cooling portfolio, positioning it for long-term growth in high-tech markets.
The outlook for ECL is positive, supported by strong analyst buy ratings (75.68%) and strategic expansions, but risks include execution of recent acquisitions and cost pressures. The stock's current valuation multiples, such as a P/E of 36.79, suggest premium pricing that requires sustained earnings growth to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Ecolab Inc.
Ecolab produces and markets cleaning and sanitation products for the hospitality, healthcare, and industrial markets. The firm is the global market share leader in this category with a wide array of products and services, including dish and laundry washing systems, pest control, and infection control products. The company has a strong hold on the U.S. market and is looking to increase its profitability abroad. Additionally, Ecolab serves customers in water, manufacturing, and life sciences end markets, selling customized solutions.
Read more on ECL →
